|
|
|
Market Research Report
The Pricing and Reimbursement Environment for Neurology Drugs
|
The Pricing and Reimbursement Environment for Neurology Drugs published by Decision Resources, Inc. in August, 2009. This report consists of 64 Pages and the price starts from US $ 3450.
Abstract
Introduction:
Neurological disorders will impose a growing social and fi nancial burden on
the major pharmaceutical markets as the elderly population in these countries
increases steadily. Governments and other payers recognize the pressing need
to tackle these diseases, but they also have to control the relentless growth
of healthcare expenditures. In an increasingly cost-conscious reimbursement
climate, the pharmaceutical industry must clearly demonstrate the value of
neurology drugs.
Get the Answers You Need to Shape Your Strategy:
- Health technology assessment will increasingly infl uence coverage of
neurology drugs in most markets in the future. What changes are likely in
Europe? How will government support for comparative effectiveness research
impact the U.S. market?
- The United States has the highest overall prices of any of the major
pharmaceutical markets, but prices for neurology drugs vary widely from
country to country. How do European and Japanese prices for bestselling
neurology drugs compare with prices in the United States? Which drugs in this
therapeutic area are more expensive in Europe and Japan than in the United
States?
- European reimbursement authorities limit access to high-priced neurology
drugs. Which agents are key targets for reimbursement restrictions in Europe?
What role do health technology assessment bodies play in regulating the use of
drugs in this therapeutic area?
- The Japanese government has not employed the types of cost-containment
measures used in the United States and Europe. What is the government
considering with regard to the regular price revision process? What are the
prospects for long-listed drugs subject to generics competition?
Scope:
- International price comparisons for neurology drugs: Alzheimer' s disease
therapies; Parkinson' s disease therapies; multiple sclerosis therapies;
antiepileptics; migraine therapies.
- Reimbursement environment in the United States, France, Germany, Italy,
Spain, the United Kingdom, and Japan: general environment; Alzheimer' s disease
therapies; Parkinson' s disease therapies; multiple sclerosis therapies;
antiepileptics; migraine therapies.
- Outlook and implications for the pharmaceutical industry: impact of
healthcare reform in the United States; cost-containment trends; prospects for
biosimilars; increasing use of health technology assessment; innovative
approaches to pricing and reimbursement.
Mentioned in This Report - Drugs:
- Almotriptan (Ortho-McNeil' s Axert/Almogran)
- Amantadine (Novartis/Alliance Pharma/Endo' s Symmetrel; Roche' s Mantadan;
Bristol-Myers Squibb' s Mantadix; generics)
- Apomorphine (Britannia Pharmaceuticals' Britaject Pen/APO-go Pen; Chiesi' s
Apofin; Aguettant/Cephalon' s Apokinon; Vernalis' s Apokyn)
- Azathioprine (Prometheus' s Imuran, GlaxoSmithKline' s Imurel/Imurek/Imuran,
generics)
- Benztropine (Ovation Pharmaceuticals' Cogentin, generics)
- Biperiden (Dainippon Sumitomo/Desma/Par Pharma' s Akineton, generics)
- Bromocriptine (Novartis/Meda' s Parlodel, generics)
- Cabergoline (Pfizer' s Cabaser/Cabaseril/Dostinex, generics)
- Carbamazepine (Novartis' s Tegretol/Tegretol XR, Shire Pharmaceuticals'
Carbatrol, generics)
- Clobazam (Sanofi-Aventis' s Frisium/Noiafren/Urbanyl, Dainippon Sumitomo' s
Mystan, generics)
- Clonazepam (Roche' s Klonopin, generics)
- Cyclophosphamide (Onko' s Cytoxan, Baxter' s Endoxan, generics)
- Diazepam (Roche' s Valium, Astellas' s Horizon, Takeda Yakuhin Kogyo' s
Cercine, other brands, generics)
- Divalproex sodium (valproate semisodium) (Abbott/Sanofi-Aventis' s
Depakote/Depakote ER)
- Donepezil (Eisai/Pfizer' s Aricept, Bracco' s Memac)
- Duodopa (Solvay/Orphan Europe' s Duodopa)
- Eletriptan (Pfizer' s Relpax)
- Entacapone (Novartis' s Comtan; Orion' s Comtess)
- Entacapone-levodopa-carbidopa (Novartis/Orion' s Stalevo)
- Ethosuximide (Pfizer' s Zarontin/Suxinutin, generics)
- Etizolam (Mitsubishi Tanabe' s Depas, generics)
- Felbamate (Meda' s Felbatol, Schering Plough/Essex' s Taloxa)
- Frovatriptan (Endo Pharmaceuticals/Menarini' s Frova)
- Gabapentin (Pfizer' s Neurontin/Gabapen, generics)
- Galantamine (Shire Pharmaceuticals/Janssen/Ortho-McNeil Neurologics'
Reminyl/Razadyne, generics)
- Glatiramer acetate (Teva' s Copaxone)
- Interferon-beta-1a (intramuscular) (Biogen Idec' s Avonex)
- Interferon-beta-1a (subcutaneous) (Merck Serono/EMD Serono/Pfizer' s Rebif)
- Interferon-beta-1b (Bayer Schering/Bayer HealthCare' s Betaseron/Betaferon,
Novartis' s Extavia)
- Lamotrigine (GlaxoSmithKline' s Lamictal, generics)
- Levetiracetam (UCB' s Keppra)
- Levodopa (Roche' s Larodopa, generics)
- Levodopa-benserazide (Roche/Chugai Seiyaku' s Madopar/Madopar CR,
Modopar,Restex; Kyowa Hakko Kirin' s EC Doparl; Daiichi Sankyo' s Neodopasol;
generics)
- Levodopa-carbidopa (Bristol-Myers Squibb/DuPont Pharma' s Sinemet/Sinemet
CR, Nacom/Nacom RETARD; Daiichi Sankyo' s Neodopaston; Merck/Banyu Seiyaku' s
Menesit; UCB/Schwarz Pharma' s Parcopa; generics)
- Lisuride (Bayer Schering AG' s Dopergin/Dopergine; Cambridge Labs' Revanil;
generics)
- Memantine (Merz/Grupo Grunenthal' s Axura, Lundbeck' s Ebixa, Forest
Laboratories' Namenda )
- Methotrexate (Dava Pharmaceuticals' Rheumatrex, Barr Pharmaceuticals'
Trexall, generics)
- Methyl-prednisolone (Pfizer' s Solu-Medrol, other brands, generics)
- Mitoxantrone (Merck Serono/EMD Serono/Amgen/Wyeth' s Novantrone)
- Mycophenolate mofetil (Roche/Aspreva/Chugai' s CellCept/Munoloc)
- Naratriptan (GlaxoSmithKline' s Amerge)
- Natalizumab (Biogen Idec/Elan' s Tysabri)
- Oxcarbazepine (Novartis' s Trileptal, generics)
- Pergolide (Eli Lilly' s Celance/Pharken/Nopar/Parkotil; Eli Lilly/Valeant' s
Permax; generics)
- Phenobarbital (generics)
- Phenytoin/phenytoin ER (Pfizer' s Dilantin/Dilantin ER, generics)
- Pramipexole (Boehringer Ingelheim' s Mirapex/ Mirapexin/Sifrol)
- Prednisone (Pfizer' s Deltasone, other brands, generics)
- Pregabalin (Pfizer' s Lyrica)
- Primidone (Valeant' s Mysoline, generics)
- Rasagiline (Teva/Lundbeck' s Agilect/Azilect)
- Rivastigmine (Novartis' s Exelon, Esteve/Biofutura/ Sigma-Tau' s Prometax)
- Rizatriptan (Merck & Co.' s Maxalt)
- Ropinirole (controlled release) (GlaxoSmithKline/ SkyePharma' s Requip
XL/LP/RP/Modutab)
- Ropinirole (immediate release) (GlaxoSmithKline' s Requip)
- Rotigotine (UCB/Schwarz Pharma' s Neupro)
- Rufinamide (Eisai' s Inovelon)
- Selegiline (Somerset Pharmaceuticals/Orion' s Eldepryl, Movergan; HRA
Pharma' s Deprenyl; Chiesi' s Egibren/Seledat/Jumex Meda' s Plurimen/Antiparkin;
Bristol-Myers Squibb' s EMSAM; Fujimoto Seiyaku' s FP; generics)
- Selegiline (fast-dissolving) (Valeant/Cephalon' s Zelapar/Xilopar/Otrasel)
- Sultiame (Bayer/Desitin/Idis Pharma/Kyowa Pharmaceutical Industry' s
Ospolot, generics)
- Sumatriptan (GlaxoSmithKline' s Imigran/Imitrex)
- Sumatriptan/naproxen sodium (GlaxoSmithKline' s Treximet)
- Talipexole (Boehringer Ingelheim' s Domin)
- Tiagabine (Cephalon' s Gabitril)
- Tolcapone (Valeant Pharma/Roche' s Tasmar)
- Topiramate (Ortho-McNeil/Janssen-Cilag' s Topamax, Kyowa Hakko Kirin' s
Topina)
- Trihexyphenidyl (Wyeth Pharmaceuticals/Sanofi-Aventis/Teopharma' s Artane,
generics)
- Valproic acid (Abbott' s Depakene, Sanofi-Aventis' s Epilim/Depakine, Kyowa
Hakko Kirin' s Depakene, generics)
- Vigabatrin (Sanofi-Aventis' s Sabril, generics)
- Zolmitriptan (AstraZeneca' s Zomig/Zomigoro/AscoTop)
- Zonisamide (Dainippon Sumitomo' s Excegran, Eisai' s Zonegran)
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- International Price Comparisons for Neurology Drugs
- Overview
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Reimbursement Environment
- United States
- General Environment
- Cost-Containment Measures
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- France
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Germany
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Italy
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Spain
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- United Kingdom
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Japan
- General Environment
- Alzheimer' s Disease Therapies
- Parkinson' s Disease Therapies
- Multiple Sclerosis Therapies
- Antiepileptics
- Migraine Therapies
- Outlook and Implications for the Pharmaceutical Industry
- Healthcare Reform in the United States
- Increasing Cost-Containment Pressures
- Pricing Constraints
- Prescribing Restrictions
- Greater Use of Generics and Biosimilars
- Health Technology Assessment
- Innovative Approaches to Pricing and Reimbursement
- Key Messages for Payers
Tables
- 1. Leading Neurology Drugs
- 2. Ex-Manufacturer Prices of Select Neurology Drugs in Europe and Japan as
a Percentage of U.S. Prices, 2008
- 3. Coverage of Select Neurology Drugs by Leading U.S. Private Insurers and
Pharmacy Benefit Management Companies
- 4. U.S. Managed Care Organizations' Use of Select Cost-Containment
Measures to Control the Use of Biologic Multiple Sclerosis Therapies
- 5. Assessment of Select Neurology Drugs by France' s Transparency Commission
- 6. Timetable for Generics Competition for Leading Neurology Drugs
- 7. Proposed Topics for U.S. Comparative Effectiveness Research Related to
Neurology Drugs
Figures
- 1. Average Ex-Manufacturer Prices of Neurology Drugs as a Percentage of
U.S. Prices, 2008
- 2. Average Ex-Manufacturer Prices of Alzheimer' s Disease Therapies as a
Percentage of U.S. Prices, 2008
- 3. Average Ex-Manufacturer Prices of Parkinson' s Disease Therapies as a
Percentage of U.S. Prices, 2008
- 4. Average Ex-Manufacturer Prices of Multiple Sclerosis Therapies as a
Percentage of U.S. Prices, 2008
- 5. Average Ex-Manufacturer Prices of Antiepileptics as a Percentage of
U.S. Prices, 2008
- 6. Average Ex-Manufacturer Prices of Migraine Therapies as a Percentage of
U.S. Prices, 2008
- 7. Health Insurance Coverage of the Total U.S. Population, 1997-2007
- 8. U.S. Residents' Sources of Prescription Drug Benefits, July 2008
- 9. Sources of Healthcare Funding for U.S. Residents by Neurological
Disease, 2008
- 10. Impact of Antiepileptic Switching on U.S. Patients
- 11. Average German Retail Prices of Reference-Priced Neurology Drugs as a
Percentage of Their Respective Reference Prices, 2009
- 12. Copayment-Exempt Neurology Drugs in Germany by Compound, July 2009
- 13. U.S. Managed Care Organizations' Likelihood of Using Step-Therapy
Protocols or Prior Authorization to Promote the Use of Biosimilar
Interferon-Beta-1b
- 14. U.S., French, and German Neurologists' Anticipated Rates of Adoption
for Biosimilar Interferon-Betas
|
 |
